Michael Kaseta Sells 3,892 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,892 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the sale, the chief financial officer now owns 311,076 shares of the company’s stock, valued at $3,456,054.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Tuesday, September 3rd, Michael Kaseta sold 1,079 shares of Liquidia stock. The shares were sold at an average price of $9.50, for a total value of $10,250.50.

Liquidia Stock Performance

LQDA stock opened at $11.46 on Friday. The stock’s 50 day moving average price is $10.42 and its 200 day moving average price is $11.97. The firm has a market cap of $875.70 million, a P/E ratio of -7.35 and a beta of 0.22. Liquidia Co. has a 1 year low of $5.71 and a 1 year high of $16.99.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. On average, research analysts predict that Liquidia Co. will post -1.69 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

Hedge funds have recently modified their holdings of the company. Patient Square Capital LP purchased a new position in shares of Liquidia during the first quarter valued at approximately $105,942,000. Vanguard Group Inc. lifted its stake in shares of Liquidia by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock worth $42,587,000 after purchasing an additional 43,352 shares during the period. Farallon Capital Management LLC acquired a new stake in shares of Liquidia during the first quarter worth $30,311,000. Whitefort Capital Management LP grew its position in shares of Liquidia by 45.8% in the first quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock valued at $4,980,000 after purchasing an additional 106,049 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in Liquidia by 119.4% in the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after purchasing an additional 125,315 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of analyst reports. HC Wainwright decreased their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research note on Monday, August 19th. Bank of America reduced their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. BTIG Research decreased their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Finally, Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).